- Report
- February 2024
Czech Republic
From €2290EUR$2,500USD£1,946GBP
From €2290EUR$2,500USD£1,946GBP
From €2290EUR$2,500USD£1,946GBP
- Report
- February 2024
Japan, United States, ... Japan, United States, Europe, Global
From €16947EUR$18,500USD£14,403GBP
- Report
- February 2024
Canada, Mexico, North America Canada, Mexico, North America
From €8703EUR$9,500USD£7,396GBP
- Report
- February 2024
France, Germany, ... France, Germany, Italy, Spain, United Kingdom, Europe
From €11451EUR$12,500USD£9,732GBP
- Report
- February 2024
Middle East
From €8703EUR$9,500USD£7,396GBP
- Report
- February 2024
Latin America
From €13283EUR$14,500USD£11,289GBP
- Report
- February 2024
Europe
From €17863EUR$19,500USD£15,182GBP
- Report
- February 2024
Asia Pacific
From €13283EUR$14,500USD£11,289GBP
- Report
- February 2024
Africa
From €5954EUR$6,500USD£5,061GBP
- Report
- February 2024
Global
From €26108EUR$28,500USD£22,189GBP
- Report
- October 2022
Thailand
From €2290EUR$2,500USD£1,946GBP
- Report
- October 2022
Canada, Mexico, North America Canada, Mexico, North America
From €8703EUR$9,500USD£7,396GBP
- Report
- August 2022
Asia Pacific
From €13283EUR$14,500USD£11,289GBP
- Report
- August 2022
Latin America
From €13283EUR$14,500USD£11,289GBP
- Report
- July 2022
Global
From €32062EUR$35,000USD£27,250GBP
- Report
- April 2022
Global
From €2244EUR$2,450USD£1,907GBP
- Report
- April 2022
Global
From €2611EUR$2,850USD£2,219GBP
- Report
- April 2022
Global
From €3527EUR$3,850USD£2,997GBP

Hemostasis is a process that helps to stop bleeding and is a part of the larger coagulation and hemostasis testing market. This market includes products and services used to diagnose and monitor bleeding and clotting disorders. Tests used in this market include prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), fibrinogen, and platelet aggregation. These tests are used to diagnose and monitor conditions such as hemophilia, thrombocytopenia, and von Willebrand disease.
The coagulation and hemostasis testing market is driven by the increasing prevalence of bleeding and clotting disorders, the growing demand for point-of-care testing, and the development of new technologies. Companies in this market include Siemens Healthineers, Roche Diagnostics, Abbott Laboratories, Sysmex Corporation, and Alere Inc. Show Less Read more